Associate Professor Greg Arndt joined Children's Cancer Institute in 2008 to establish the Australian Cancer Research Foundation (ACRF) Drug Discovery Centre. As Head of the Centre, Greg leads a team of scientists whose work focuses on the discovery of novel small molecule therapeutics, which has involved pivotal roles in the partnerships with the Cancer Therapeutics Cooperative Research Centre (CTx) and the Zero Childhood Cancer Program. Greg is also Head of Drug Discovery for the THINK drug discovery initiative, which represents an end-to-end pipeline of drug discovery and development capabilities committed to finding new treatments for paediatric cancers.
After completing his PhD at the University of Saskatchewan, Canada, Greg worked as a postdoctoral fellow in industry at the RW Johnson Pharmaceutical Research Institute. Before joining Children’s Cancer Institute, he was Research Director and Project Leader with Johnson & Johnson Research Pty Ltd, where he spent 15 years in increasingly senior roles focusing on cell-based screening as a tool for developing novel therapeutics.
Greg has held several academic roles, including Adjunct Senior Lecturer (2005–2007) and Senior Visiting Fellow (2007–2013) in the School of Biotechnology and Biomolecular Science at UNSW Sydney, and is currently an Associate Professor in the Faculty of Medicine, UNSW Sydney. He has successfully trained several Honours and PhD students, and his research has led to numerous publications in high-quality journals and the submission of several international patent applications. His expertise spans target discovery and validation, development of novel technology platforms, high throughput screening, and early-stage drug discovery.